Advanced search
1 file | 457.87 KB Add to list

The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model

(2012) ACTA CLINICA BELGICA. 67(2). p.108-119
Author
Organization
Abstract
Substantial evidence from randomised clinical trials has demonstrated that long-acting risperidone (RLAI) is efficacious and well tolerated in patients with schizophrenia. Recently, a long-term naturalistic study of treatment practices in Belgium, the electronic Schizophrenia Treatment Adherence Registry (e-STAR), reported that treatment with RLAI is associated with improvements in adherence and long-term outcomes. The present report describes the results of a budget impact model that analysed the Belgian e-STAR data, together with other available data, over a 3-year time horizon, in order to establish the potential impact of treatment with RLAI on total healthcare costs in Belgium. The model framework combined medical resource utilisation with costs of the population of interest in order to quantify the costs, and cost offsets, of RLAI treatment. For the purpose of this budget impact model, it was assumed that among patients who would discontinue their previous antipsychotic medication, 6.7% of patients would be switched to RLAI. The overall cost savings to the Belgian healthcare system were calculated to be (sic)2.3 million in Year 1, (sic)3.7 million in Year 2 and (sic)4.4 million in Year 3. The majority of these cost-savings resulted from the substantial reduction in hospitalisation costs associated with RLAI treatment. This report indicates that improvements in adherence and long-term outcomes previously demonstrated for RLAI treatment in Belgium may result in substantial cost benefits to the country's healthcare system.
Keywords
budget impact analysis, antipsychotic, adherence, cost-effectiveness, long-acting risperidone injection, long-term outcomes, relapse, schizophrenia, QUALITY-OF-LIFE, NEUROLEPTIC MALIGNANT SYNDROME, COST-EFFECTIVENESS ANALYSIS, INJECTABLE RISPERIDONE, SCHIZOAFFECTIVE DISORDER, STABLE PATIENTS, ANTIPSYCHOTIC MEDICATION, DEPOT ANTIPSYCHOTICS, RESOURCE UTILIZATION, OPEN-LABEL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 457.87 KB

Citation

Please use this url to cite or link to this publication:

MLA
Annemans, Lieven, I Eijgelshoven, A Smet, et al. “The Impact of Treatment with Risperidone Long-acting Injection on the Belgian Healthcare System: Results from a Budget Impact Model.” ACTA CLINICA BELGICA 67.2 (2012): 108–119. Print.
APA
Annemans, Lieven, Eijgelshoven, I., Smet, A., Jacobs, A., & Bergman, G. (2012). The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model. ACTA CLINICA BELGICA, 67(2), 108–119.
Chicago author-date
Annemans, Lieven, I Eijgelshoven, A Smet, A Jacobs, and G Bergman. 2012. “The Impact of Treatment with Risperidone Long-acting Injection on the Belgian Healthcare System: Results from a Budget Impact Model.” Acta Clinica Belgica 67 (2): 108–119.
Chicago author-date (all authors)
Annemans, Lieven, I Eijgelshoven, A Smet, A Jacobs, and G Bergman. 2012. “The Impact of Treatment with Risperidone Long-acting Injection on the Belgian Healthcare System: Results from a Budget Impact Model.” Acta Clinica Belgica 67 (2): 108–119.
Vancouver
1.
Annemans L, Eijgelshoven I, Smet A, Jacobs A, Bergman G. The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model. ACTA CLINICA BELGICA. 2012;67(2):108–19.
IEEE
[1]
L. Annemans, I. Eijgelshoven, A. Smet, A. Jacobs, and G. Bergman, “The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model,” ACTA CLINICA BELGICA, vol. 67, no. 2, pp. 108–119, 2012.
@article{3136609,
  abstract     = {Substantial evidence from randomised clinical trials has demonstrated that long-acting risperidone (RLAI) is efficacious and well tolerated in patients with schizophrenia. Recently, a long-term naturalistic study of treatment practices in Belgium, the electronic Schizophrenia Treatment Adherence Registry (e-STAR), reported that treatment with RLAI is associated with improvements in adherence and long-term outcomes. The present report describes the results of a budget impact model that analysed the Belgian e-STAR data, together with other available data, over a 3-year time horizon, in order to establish the potential impact of treatment with RLAI on total healthcare costs in Belgium. The model framework combined medical resource utilisation with costs of the population of interest in order to quantify the costs, and cost offsets, of RLAI treatment. For the purpose of this budget impact model, it was assumed that among patients who would discontinue their previous antipsychotic medication, 6.7% of patients would be switched to RLAI. The overall cost savings to the Belgian healthcare system were calculated to be (sic)2.3 million in Year 1, (sic)3.7 million in Year 2 and (sic)4.4 million in Year 3. The majority of these cost-savings resulted from the substantial reduction in hospitalisation costs associated with RLAI treatment. This report indicates that improvements in adherence and long-term outcomes previously demonstrated for RLAI treatment in Belgium may result in substantial cost benefits to the country's healthcare system.},
  author       = {Annemans, Lieven and Eijgelshoven, I and Smet, A and Jacobs, A and Bergman, G},
  issn         = {0001-5512},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {budget impact analysis,antipsychotic,adherence,cost-effectiveness,long-acting risperidone injection,long-term outcomes,relapse,schizophrenia,QUALITY-OF-LIFE,NEUROLEPTIC MALIGNANT SYNDROME,COST-EFFECTIVENESS ANALYSIS,INJECTABLE RISPERIDONE,SCHIZOAFFECTIVE DISORDER,STABLE PATIENTS,ANTIPSYCHOTIC MEDICATION,DEPOT ANTIPSYCHOTICS,RESOURCE UTILIZATION,OPEN-LABEL},
  language     = {eng},
  number       = {2},
  pages        = {108--119},
  title        = {The impact of treatment with risperidone long-acting injection on the Belgian healthcare system: results from a budget impact model},
  url          = {http://dx.doi.org/10.2143/ACB.67.2.2062640},
  volume       = {67},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: